A natural fiber complex reduces body weight in the overweight and obese: A double-blind, randomized, placebo-controlled study

Obesity

Volumn 21, Issue 1, 2013, Pages 58-64

  Grube, Barbara ^a   Chong, Pee Win ^b   Lau, Kai Zhia ^b   Orzechowski, Hans Dieter ^c  

^a Practice for General Medicine   (Germany)

^b InQpharm Europe Ltd   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; IQP G 002AS; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIETARY FIBER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE; FEMALE; HEART RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; NUTRITIONAL COUNSELING; OBESITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; ANTI-OBESITY AGENTS; BODY COMPOSITION; BODY MASS INDEX; DIETARY FIBER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; OBESITY; OPUNTIA; OVERWEIGHT; PHYTOTHERAPY; PLANT PREPARATIONS; WAIST CIRCUMFERENCE; WEIGHT LOSS;

OPUNTIA;

EID: 84876298374     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2012.165     Document Type: Article

References (30)

1. Stevens G, Mascarenhas M, Mathers C. Global health risks: progress and challenges. Bull World Health Organ 2009;87:646.
2. Finucane MM, Stevens GA, Cowan MJ et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9-1 million participants. Lancet 2011;377:557-567.
3. Uwaifo AGI, Editor C, Griffing GT. Obesity. Medscape Reference. 2011. Available at: 〈http://emedicine.medscape.com/article/123702-overview〈. Accessed 20 August 2011.
4. Wellman NS, Friedberg B. Causes and consequences of adult obesity: health, social and economic impacts in the United States. Asia Pac J Clin Nutr 2002;11(Suppl 8): S705-S709.
5. de Wit L, Luppino F, van Straten A et al. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res 2010;178:230-235.
6. Simon GE, Ludman EJ, Linde JA et al. Association between obesity and depression in middle-aged women. Gen Hosp Psychiatry 2008;30:32-39. (Pubitemid 350299503)
7. Simon GE, Von Korff M, Saunders K et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 2006;63: 824-830.
8. Wadden TA, Stunkard AJ. Social and psychological consequences of obesity. Ann Intern Med 1985;103:1062-1067. (Pubitemid 16211933)
9. Hammond RA, Levine R. The economic impact of obesity in the United States. Diabetes Metab Syndr Obes 2010;3:285-295.
10. Fry J, Finley W. The prevalence and costs of obesity in the EU. Proc Nutr Soc 2005;64:359-362. (Pubitemid 41160765)
11. Bray GA, Paeratakul S, Popkin BM. Dietary fat and obesity: a review of animal, clinical and epidemiological studies. Physiol Behav 2004;83:549-555. (Pubitemid 40038504)
12. Sjöström L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-172. (Pubitemid 28327800)
13. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235-242. (Pubitemid 29058112)
14. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000;8:49-61.
15. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-167.
16. Collazo-Clavell ML. Safe and effective management of the obese patient. Mayo Clin Proc 1999;74:1255-9; quiz 1259.
17. Johansson K, Neovius K, DeSantis SM, Rössner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009;10:564-575.
18. US Food and Drug Administration. Safety orlistat (marketed as Alli and Xenical): early communication about an ongoing safety review. 2009:180057-180057.
19. Bachmann C. Ein Fasernkomplex zur Gewichts- reduktion und -kontrolle. Ars Medici thema Phytotherapie 2010:25-27.
20. International Association for the Study of Obesity. Overweight and Obesity in the EU27. International Association for the Study of Obesity: London, 2008.
21. Trumbo P, Schlicker S, Yates AA, Poos M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc 2002;102:1621-1630. (Pubitemid 40434081)
22. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord 1993;17:241-244. (Pubitemid 23133355)
23. Drent M, Larsson I, William-Olsson T et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995;19:221-226.
24. US Food and Drug Administration. guidance for industry developing products for weight management guidance for industry developing products for weight management. 2007.
25. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), North American Association for the Study of Obesity (NAASO). The practical guide: Identification, evaluation and treatment of overweight and obesity in adults. 2000.
26. Phelan S, Wadden TA, Berkowitz RI et al. Impact of weight loss on the metabolic syndrome. Int J Obes (Lond) 2007;31:1442-1448. (Pubitemid 47339915)
27. Jull AB, Rodgers A, Walker N. Honey as a topical treatment for wounds. Cochrane Database Syst Rev 2008:CD005083.
28. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998;54:125-132. (Pubitemid 28204265)
29. Romero-Corral A, Virend K, Sierra-Johnson J et al. Accuracy of body mass index to diagnose obesity in the US adult population. Int J Obes (Lond) 2008;32:959-966. (Pubitemid 351986216)
30. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 2001;25: 1095-1099. (Pubitemid 32566068)